title: We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity.
authors: Young-Hoon
authors: YH
authors: Jeong
authors: Kevin P
authors: KP
authors: Bliden
authors: Udaya S
authors: US
authors: Tantry
authors: In-Suk
authors: IS
authors: Kim
authors: Yongwhi
authors: Y
authors: Park
authors: Paul A
authors: PA
authors: Gurbel
mesh_terms: D000284:Administration, Oral; D000483:Alleles; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D044466:Asian People; D001792:Blood Platelets / Q000378:metabolism; D000077407:Cilostazol; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000235:genetics / Q000628:therapy; D065731:Cytochrome P-450 CYP2C19; D054855:Drug-Eluting Stents; D005006:Ethnicity; D005838:Genotype; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010976:Platelet Count; D015995:Prevalence; D012107:Research Design; D013777:Tetrazoles / Q000494:pharmacology*; D013927:Thrombosis / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D000077407:Cilostazol